Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
EyePoint Pharmaceuticals Inc has a consensus price target of $32.78 based on the ratings of 10 analysts. The high is $55 issued by Guggenheim on May 18, 2023. The low is $15 issued by Jefferies on August 28, 2024. The 3 most-recent analyst ratings were released by Jefferies, JP Morgan, and Chardan Capital on August 28, 2024, August 13, 2024, and June 28, 2024, respectively. With an average price target of $24 between Jefferies, JP Morgan, and Chardan Capital, there's an implied 185.71% upside for EyePoint Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for EyePoint Pharmaceuticals (NASDAQ:EYPT) was reported by Jefferies on August 28, 2024. The analyst firm set a price target for $15.00 expecting EYPT to rise to within 12 months (a possible 78.57% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) was provided by Jefferies, and EyePoint Pharmaceuticals initiated their buy rating.
There is no last upgrade for EyePoint Pharmaceuticals
There is no last downgrade for EyePoint Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on August 28, 2024 so you should expect the next rating to be made available sometime around August 28, 2025.
While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a initiated with a price target of $0.00 to $15.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $8.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.